[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362649-105":59,"doc-detail-362649-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","growth-rate-driven-modelling-suggests-that-phenotypic-adaptation-drives-drug-resistance-in-brafv600e-mutant-melanoma","Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma","","Phenotypic adaptation, the capacity of cancer cells to switch phenotype under external pressures, is identified as a driver of drug resistance in BRAFV600E-mutant melanoma. A theoretical framework is developed from growth-rate data of WM239A-BRAFV600E cells treated with the BRAF inhibitor encorafenib. An individual-based model assigns each cell to discrete, plastic phenotype states linked to drug-dependent net growth rates and resistance. Candidate transition models are compared against in vitro growth curves, indicating adaptation toward high net-growth states that evade drug effects. The model explains why intermittent therapy can outperform continuous dosing and proposes leveraging adaptation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/growth-rate-driven-modelling-suggests-that-phenotypic-adaptation-drives-drug-resistance-in-brafv600e-mutant-melanoma/362649/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/growth-rate-driven-modelling-suggests-that-phenotypic-adaptation-drives-drug-resistance-in-brafv600e-mutant-melanoma/362649.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the central hypothesis of the study regarding drug resistance?","Question",{"text":112,"@type":113},"Phenotypic adaptation, i.e., phenotype switching without genetic mutation, drives drug resistance in BRAFV600E-mutant melanoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is phenotypic adaptation quantified in the proposed approach?",{"text":117,"@type":113},"The study builds a theoretical individual-based model where plastic phenotype states are linked to drug-dependent net growth rates.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the model comparisons suggest about therapy schedules?",{"text":121,"@type":113},"Model-matched simulations indicate that intermittent treatments can outperform continuous treatments by steering populations toward states that maintain high net growth under drug pressure.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362649,1791122033,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-026-09760-2](https://doi.org/10.1038/s42003-026-09760-2) |  |  |\n| Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma\u003Cbr> Check for updates |  |  |\n| Sara Hamis 1 , Alexander P. Browning 2, Adrianne L. Jenner3, Chiara Villa4,5, Philip K. Maini 2 & Tyler Cassidy6 |  |  |\n| Phenotypic adaptation, the ability of cells to change phenotype in response to external pressures, has been identiﬁed as a driver of drug resistance in cancer. To quantify phenotypic adaptation in BRAFV600E-mutant melanoma, we develop a theoretical model informed by growth-rate data of WM239A-BRAFV600E cells challenged with the BRAF-inhibitor encorafenib. We use an individualbased model (IBM) in which each cell is described by one of multiple discrete and plastic phenotype states that are directly linked to drug-dependent net growth rates and, by extension, drug resistance. To describe how cells transition between phenotype states, we explore a gamut of candidate models common in the mathematical biology literature. Comparing these on their ability to reproduce in vitro growth curves, data-matched simulations suggest that phenotypic adaptation is directed towards states of high net growth rates, enabling the evasion of drug-effects. The model subsequently providesan explanation for when and why intermittent treatments outperform continuous treatments in the studied system, and demonstrates the beneﬁts of not only targeting, but also leveraging, phenotypic adaptation in treatment protocols. Building on the IBM, we present a ﬂexible mathematical methodology based on ordinary differential equations to compare responses to continuous and intermittent treatments through long-term effective net growth rates. |  |  |\n| Over50%ofmelanoma cases present with BRAFV600mutations that result in constitutive activation of the Mitogen Activated Protein Kinase (MAPK)1,2. Consequently, targeted small molecule therapies that selectively inhibit mutant BRAF signalling have been developed over the last decades and are now part of the standard of care for BRAF-mutant melanoma. While these targeted therapies have led to a remarkable increase in progression free survival, treatment resistance inevitably develops and limits long-term survival3. This drug resistance in BRAF-mutant melanoma, and other solid tumours, is increasingly understood as a result of intratumoural heterogeneity, which has long been viewed through the lens of inter-clonal differences4–6. However, a growing body of work implicates cell plasticity, i.e., phenotypic adaptation without associated genetic mutations, as a key component of therapy resistance in melanoma1,7,8. | Advances in transcriptomics and multi-omics have led to the identiﬁcation ofreversible and adaptive phenotype changes that confer treatment resistance and are mediated by a number of complex physiological factors on the single-cell level9–11. As systems-level experiments of the complex interactions driving these adaptations are currently intractable, computational models have become increasingly important to our understanding of how therapeutic selection pressure shapes the epigenetic evolution of malignant tumours12–14. Such evolution is driven by epigenetic changes in cancer cells, i.e., changes in gene expression that do not involve changes in the cells’ DNA sequence15.\u003Cbr>Phosphorylated, i.e., activated, ERK is often considered to be the main output of interest in pathway-level studies of BRAF-mutated melanoma. This follows from the fact that activated ERK phosphorylates multiple |  |\n\n1Department of Information Technology, Uppsala University, Uppsala, Sweden. 2Mathematical Institute, University of Oxford, Oxford, UK. 3School of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. 4Sorbonne Université, CNRS, Université de P","cbCaikNDZ2TGNx5l","https://ap.wps.com/l/cbCaikNDZ2TGNx5l","pdf",2136777,12,"English","# Introduction\n## Background on BRAFV600E melanoma and resistance\n## Role of cell plasticity and computational modelling","[{\"question\":\"What is the central hypothesis of the study regarding drug resistance?\",\"answer\":\"Phenotypic adaptation, i.e., phenotype switching without genetic mutation, drives drug resistance in BRAFV600E-mutant melanoma.\"},{\"question\":\"How is phenotypic adaptation quantified in the proposed approach?\",\"answer\":\"The study builds a theoretical individual-based model where plastic phenotype states are linked to drug-dependent net growth rates.\"},{\"question\":\"What do the model comparisons suggest about therapy schedules?\",\"answer\":\"Model-matched simulations indicate that intermittent treatments can outperform continuous treatments by steering populations toward states that maintain high net growth under drug pressure.\"}]","Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma | PDF",1790148683,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/578a7457398f785163317e6db068f06c.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74fab29c7ba0c70416d1398bf85f1254.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d3dd3cf9ee94a61d197fd3aab69c18f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5eec532b53c7278d88f5779f39af8fa.webp",980,1301]